Compare WSO & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSO | WAT |
|---|---|---|
| Founded | 1945 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 17.4B |
| IPO Year | N/A | 1995 |
| Metric | WSO | WAT |
|---|---|---|
| Price | $349.77 | $394.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $435.00 | $382.14 |
| AVG Volume (30 Days) | 381.1K | ★ 531.7K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | ★ 3.82 |
| EPS | ★ 12.87 | 10.88 |
| Revenue | ★ $7,414,495,000.00 | $3,105,638,000.00 |
| Revenue This Year | N/A | $7.96 |
| Revenue Next Year | $4.21 | $6.32 |
| P/E Ratio | ★ $27.01 | $36.30 |
| Revenue Growth | N/A | ★ 6.90 |
| 52 Week Low | $323.05 | $275.05 |
| 52 Week High | $535.40 | $423.56 |
| Indicator | WSO | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 61.33 |
| Support Level | $337.73 | $386.09 |
| Resistance Level | $356.99 | $403.80 |
| Average True Range (ATR) | 10.38 | 9.63 |
| MACD | 2.70 | -1.66 |
| Stochastic Oscillator | 73.88 | 53.55 |
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.